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Summary This phase II study evaluates the efficacy and toxicity of a prolonged schedule of oral etoposide in
patients with measurable advanced ovarian cancer resistant to, or relapsed following, platinum-based
chemotherapy. Forty-seven patients participated, 20 of whom had received more than one prior treatment.
Seventy-seven per cent had evidence of disease progression during or within 6 months of the previous
chemotherapy. Initially, oral etoposide, 50 mg b.d. (regardless of patient size), was given for 14 days on a
21-day cycle. However, after encountering toxicity, the schedule was modified to 7 days' treatment escalating
to 10 then 14 days if well tolerated. Among 41 assessable patients there were two complete and eight partial
objective responses (24% response rate; 95% confidence interval 12-41%). Nine further patients (22%) had
stable disease, four with a sustained fall of > 50% in CA-125. Median duration of response or stable disease
was 35 weeks (range 21-49). Overall median survival was 41 weeks from study entry (range 2 to 96+ weeks).
Toxicity for most patients was mild, but sporadic severe myelotoxicity occurred, with two treatment-related
deaths. Risk factors for severe toxicity were: performance status 3; hepatic impairment; renal impairment. We
conclude that oral etoposide has activity in platinum-resistant ovarian cancer and that it is a useful palliative
therapy. It has significant toxicity which may be avoided by appropriate patient selection and an escalating-
duration schedule.
Platinum-based chemotherapy protocols have high initial re-
sponse rates in patients with epithelial ovarian cancer. How-
ever, when the disease is primarily resistant, or when relapse
occurs within a year, the prospects for second-line treatment
are bleak. Phase II studies in this situation, either with single
agents (Sutton et al., 1989; Coleman et al., 1989; 1990;
Manetta et al., 1990) or with combination chemotherapy
(Belinson et al., 1986; Benedetti-Panici et al., 1990; Pater et
al., 1987), have generally yielded few responses, of short
duration. Even the promising new agent, taxol, gives re-
sponses in only 20-30% of this group of patients (Einzig et
al., 1992; McGuire et al., 1989; Trimble et al., 1993).
Platinum-resistant cell lines show little or no cross-
resistance to etoposide in vitro, making it a potential can-
didate for use either in combination with platinum as
primary treatment or, later, as second-line treatment for this
disease. In the five previously reported studies using single-
agent etoposide as second-line treatment, a total of 247
patients were treated, with 51 responses (complete and partial
responses; 21%). These studies all employed 3 or 4 day
intravenous or oral schedules (Kuhnle et al., 1988; Kavanagh
et al., 1989; Eckhardt et al., 1990; Hillcoat et al., 1985;
Hansen et al., 1990).
Etoposide interacts with topoisomerase II, which is active
during the late S and early G2 phases of the cell cycle. It is
consequently schedule dependent in vitro (Hill et al., 1981),
and studies in small cell lung cancer (SCLC) have also dem-
onstrated marked clinical schedule dependency: when a total
dose of 500 mgm2 was given either as a single 24 h i.v.
infusion or divided into five daily fractions, the response
rates to single day and 5 day treatments were 10% and 90%
respectively (Slevin et al., 1989a). A subsequent study com-
paring the same total dose given intravenously over either 5
days or 8 days suggested some further benefit in terms of
reduced myelotoxicity with the longer schedule (Slevin et al.,
1989b). Protracted oral schedules have subsequently given
good response rates in SCLC and are generally well tolerated
(Clark et al., 1990). Furthermore, responses to protracted
oral etoposide have been seen in patients with SCLC and
germ cell tumours which had previously progressed through
combination chemotherapy including etoposide (Greco et al.,
1990; Miller & Einhorn, 1990).
For these reasons we elected to re-evaluate etoposide in the
treatment of epithelial ovarian cancer using a prolonged oral
administration schedule. The setting chosen was a multi-
institutional phase II study for patients with relapsed disease,
previously treated with at least one platinum-based regimen.
The schedule chosen was one of those previously used in
non-pretreated small cell lung cancer patients: 50 mg b.d. for
14 days on a 3 week cycle (Clark et al., 1990). This protocol
subsequently had to be modified because of toxicity.
Patients and methods
This prospective study was initiated in November 1990 by
the London Gynaecological Oncology Group (LGOG).
Patients were treated by medical oncologists at St. George's
Hospital, London; The Royal London Hospital, London; St.
Bartholomew's Hospital, London; The Royal Marsden Hos-
pital, London; Guy's Hospital, London; and Queen Mary's
Hospital, Sidcup, Kent, UK. The study was approved by the
Clinical Research Ethics Committees of these institutions.
Patients were informed of the investigational nature of the
treatment and of its expected toxicities before giving written
consent.
Eligibility criteria
To be eligible, patients were required to have assessable,
histologically confirmed epithelial ovarian cancer with
radiological and/or clinical evidence of disease progression
during the preceding 2 months. Previous treatment with at
least one platinum-containing regimen was mandatory and
the treating physician had to be satisfied that further
platinum-based treatment was inappropriate. The protocol
required an Eastern Cooperative Oncology Group (ECOG)
performance status of 0, or 2 at study entry, however five
patients with ECOG status 3 were entered (all of whom fared
badly) and have been included in the analysis. A granulocyte
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count of > 1.5 x I09 - 1 and platelet count of > 100 x I09 l'-
were required. Patients with serum bilirubin >30imol ['
were ineligible, as were those with unresolved bowel obstruc-
tion or other impediment to oral therapy. Age and renal
function were not limited but, in accordance with previous
data on the effect of renal function on etoposide phar-
macokinetics and toxicity, a dose reduction was made if
serum creatinine exceeded 130 jtmol 1' (Joel et al., 199la).
One patient with renal impairment had a pharmacokinetics-
guided dose reduction and received 50 mg o.d. alternating
with b.d. (see below).
Treatment and monitoring
Soft gelatin etoposide 50 mg capsules were used, which also
contain glycerol and polyethylene glycol (Bristol Myers Phar-
maceuticals, UK). Initially, the starting dose was 50 mg b.d.
for 14 days but, following four occurrences of WHO grade 4
myelotoxicity with one treatment-related death among the
first 13 patients, the protocol was modified. Subsequent
patients received 50 mg b.d. for 7 days in cycle 1, 10 days in
cycle 2 and 14 days in cycles 3-6, each escalation being made
only if no toxicity of grade 3-4 had occurred.
Treatment was given on a 21 day cycle, to a maximum of
six cycles. The cycle was delayed 1 week if the granulocyte
count was <1.5 x 1091- or the platelet count was
< 100 X 109 1' on day 1. The full blood count was repeated
on day 8 and day 15 of each cycle. Patients were interviewed
and examined on day 1 of each treatment cycle and non-
haematological toxicity was recorded using World Health
Organization (WHO) criteria (WHO, 1979).
Patient compliance was not formally assessed, but alopecia
was observed in all patients who completed two or more
treatment cycles. A previous study of compliance with the
same schedule of oral etoposide in small cell lung cancer
patients demonstrated overall compliance of >90% (Lee et
al., 1993).
The response to etoposide treatment was assessed radio-
logically (using CT scan) after the third and sixth cycles, or
sooner in the event of clinical deterioration. Patients with a
response or stable disease were reassessed at intervals not
exceeding 3 monthly during follow-up. Tumour responses
were classified in accordance with WHO criteria (WHO,
1979). The time to treatment failure was defined, in line with
these criteria, as the duration from the start of etoposide
treatment to the detection of disease progression. CA-125
measurements were made in all patients before and during
treatment and were used to guide clinical investigation but
not, in isolation, to determine response status. Patients were
deemed unassessable for response if, in the absence of any
indication of disease progression, treatment had to be stop-
ped after the first course.
Statistical design
Standard phase II stopping rules were in force, using Gehan's
plan to stop accrual if the probability of the response rate
being over 20% fell below 5% (Simon, 1989). These stopping
rules did not need to be applied.
Results
Between November 1990 and January 1993, 47 patients were
entered onto this study (see Table I). All are evaluated for
toxicity but six are not evaluable for response, one because
the marker lesion on CT scan later turned out to be a
bladder diverticulum, the others because of withdrawal after
the first cycle, without evidence of disease progression,
because of toxicity (three patients) or for personal reasons
(two patients). Sixty per cent of patients had involvement of
the liver parenchyma or distant sites. For the purposes of
comparison with other phase II studies, data are presented
both for the interval to disease progression following the
most recent chemotherapy and for the treatment-free interval
before starting oral etoposide. The study is now mature, with
only 14 patients remaining alive, three without disease pro-
gression.
Anti-tumour responses
Objective remissions were observed in 10 of 41 evaluable
patients (24% response rate, 95% confidence interval
12-41%). One patient with poorly differentiated papillary
histology, a pelvic mass, inguinal lymphadenopathy and liver
metastases, whose disease had recently progressed through
six cycles of carboplatin, had a complete remission (clinical,
CT and CA-125), lasting 38 weeks. Another, with endomet-
rioid histology, lung metastases and cervical lymphadeno-
pathy, had previously received single-agent cisplatin (which
produced partial remission, relapsing 3 months after stop-
ping) and single-agent chlorambucil (with no response). She
had a complete remission (clinical, chest radiograph, CT and
CA-125), which is ongoing at 23 weeks. Eight patients had
partial response (PR) by WHO criteria, confirmed in all cases
Table I Patient characteristics
Total entered
Assessable for response
Age: median (range)
Sites of disease at study entry
Pelvis/peritoneal cavity
Retroperitoneal
Liver parenchyma/distant
Performance status (ECOG)
0 O
2
3
Prior therapy
Cis- and/or carboplatin
Other cytotoxics
Radiotherapy
No. of previous chemotherapy protocols
1
2 or 3
Time to PD after last chemotherapy
0 (PD on treatment)
1-6 months
>6 months
Treatment-free interval
<6 months
>6 months
47
41
60 (41-76)
43 (91%)
22 (47%)
28 (60%)
10 (21%)
26 (55%)
6 (13%)
5 (11%)
47 (100%)
9 (19%)
8 (17%)
27 (57%)
20 (43%)
16 (34%)
20 (43%)
11 (23%)
28 (60%)
19 (40%)
Table II Characteristics of patients with CR, PR or SD (n = 19)
Age: median (range)
Sites of disease
Pelvis/peritoneal cavity
Retroperitoneal
Liver parenchyma/distant sites
Performance status at entry
0
1
2 or more
No. of previous chemotherapy protocols
1
2 or 3
Time to PD after last chemotherapy
0 (PD on treatment)
1-6 months
>6 months
Treatment-free interval
<6 months
> 6 months
60 (41-67)
17 (89%)
3 (16%)
7 (37%)
7 (37%)
12 (63%)
0
9 (47%)
10 (53%)
5 (26%)
10 (53%)
4 (21%)
9 (47%)
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by >50% fall or complete normalisation of serum CA-125.
PR durations were 49, 39, 35, 32, 28, 27 24+ and 21 weeks.
In addition, stable disease or lesser response (SD) lasting
16-45 weeks was seen in a further nine patients, four of
whom had a sustained fall of >50% in serum CA-125.
The median time to treatment failure for patients with CR,
PR or SD is 35 weeks. The characteristics of these 19
patients are summarised in Table II. It is of note that re-
sponses and SD were only seen in patients with performance
status 0 or 1.
Survival
Median survival for all 47 patients was 41 weeks (range
2-96+ weeks). As expected, among the assessable patients,
disease response or SD was associated with increased sur-
vival, with median survival projected at 81 weeks compared
with 24 weeks for those with progressive disease (PD) (Figure
1), although of course this is not proof of a causal relation-
ship. Patients with an objective response did not fare
significantly better than those with stable disease.
Toxicity andprotocol modification
The toxicities recorded in all 47 patients are shown in Table
III. Variable and excessive toxicity was encountered during
80-
CR, PRorSD(n= 19)
60.
0)
X 40-.
CD
20.,
E
| PD (n =22)
4 8 12 16 20 24
Time (months)
Figure 1 Cumulative survival for patients with CR, PR or SD
compared with the survival of those with PD (41 assessable
patients). When separated, the survival for patients with CR/PR
is not significantly better than for those with SD.
Table III Worst toxicity
Toxicity WHO grade
(n = 47patients) 0 1 2 3 4
Haematological 12 1 1 9 9 6
Infection 43 0 0 2 2a
Nausea/vomiting 15 18 8 4 2b
Stomatitis 29 5 9 2c 2c
Alopecia in all patients - not graded
No other toxicities >grade 2
Total 194 treatment cycles administered. aDied from sepsis during
nadir. bPatients with PD and bowel obstruction. CIn association with
neutropenia.
treatment of the first 13 patients at a starting dose of
50 mg b.d. for 14 days: four patients developed grade 4
myelotoxicity, one of whom died. These patients all carried
risk factors of age, poor performance status or hepatic
impairment (Table IV). Thereafter the protocol was modified
and subsequent patients received only 7 days' treatment for
the first cycle, escalating to 10 then 14 days only if no grade
3 or 4 toxicity was encountered. Of 34 patients treated on
this escalating schedule, 17 (50%) reached the full 14 day
regimen. The others continued on a 7 day (six patients) or 10
day (five patients) schedule, or had been withdrawn before
full escalation could occur. Inability to tolerate the full 14
day schedule correlated with age, performance status and
number of previous treatments, but not with mild renal or
hepatic dysfunction.
After this protocol modification, only two of 34 patients,
one with severe renal impairment, developed grade 4
myelotoxicity, and treatment was generally well tolerated.
The patient with renal impairment (glomerular filtration rate
14 ml min-) was also hypoalbuminaemic (29 gl-). She was
given a test dose on day 1, following which total plasma
etoposide pharmacokinetics was measured using a limited
sampling strategy described elsewhere (Joel et al., 1991b). A
dose reduction was calculated and a further 6 days' treatment
was given at 50 mg o.d./b.d. on alternate days. Further sam-
pling on day 7 confirmed that drug accumulation had not
occurred. However, despite this, grade 4 myelotoxicity
developed from day 11, complicated by Staphylococcus
aureus septicaemia, and the patient subsequently died.
Response in relation to toxicity and dose intensity
Taking all 41 assessable patients (original+ modified pro-
tocols), there is no correlation between the highest grade of
myelotoxicity and the response to treatment (overall x2 test,
P = 0.9). Thus, responses and disease stabilisation were seen
as commonly in patients who had only grade 0-1 myelotox-
icity as in those showing significant myelotoxicity during
treatment.
For patients on the modified protocol, there was a rela-
tionship between the ability to escalate to the full 14 day
schedule and the subsequent response. One CR and two SD
were seen among the 11 patients who could not tolerate the
full 14 day regimen (response + SD = 21%), compared with
one CR, seven PR and four SD among the 17 who could
(response + SD = 70%). However, this difference might
relate to the poorer performance status of the former group
rather than to the lower dose intensity received.
Discussion
This study demonstrates that oral etoposide has activity in
relapsed ovarian cancer. In this population of patients with
bulky and multiple sites of disease the objective response rate
of 24% (95% confidence interval 12-41%) is encouraging.
This experience is superior to that of Marzola et al. (1993),
who recently reported only one PR among 17 patients using
oral etoposide 50mgo.d. for 21 days every 4 weeks. Their
patients were more heavily pretreated (all >2 previous
treatments), but of better performance status (all 0-1) and
with a longer treatment-free interval (>6 months in 55%). It
is possible that the lower dose intensity of the 50mgo.d.
schedule was a factor.
Table IV Characteristics of patients with severe first-cycle toxicity
Performance Renal Hepatic Cycle I Haemotological Mucosal
Age status impairment impairment duration toxicity toxicity Outcome
56 3 - + 14 days 4 4 Toxic death
67 3 + + - 7 days 4 0 Toxic death
47 3 - - 14 days 4 0 Withdrawn (PD)
56 2 - + 14 days 4 3 Withdrawn (toxicity)
76 1 - - 14 days 4 3 Withdrawn (toxicity)194 M.T. SEYMOUR et al.
The result of this study should be interpreted in the light
of the published phase II studies of taxol in relapsed ovarian
cancer (Einzig et al.,1992; McGuire et al., 1989), in which a
total of 70 patients have been treated with two complete and
16 partial responses (CR + PR 26%; 95% confidence inter-
vals 16-38%). One of these studies excluded patients with
more than one previous chemotherapy treatment. Data
recently reported from the use of taxol in very heavily
pretreated patients (> 3 prior regimens) throughout the USA
suggested a response rate of 21%, with 19% SD (Trimble et
al., 1993).
Whether etoposide's activity is clinically useful depends on
the balance of treatment-induced toxicity against anticancer
activity, a judgement that must be made for individual
patients. The consistent side effect of etoposide is alopecia
which, for some but not all patients, is an important price to
pay for a modest chance of benefit. For many patients this
was the only significant side effect, but more worrying were
the episodes of severe myelotoxicity, with two treatment-
related deaths. All the affected patients had one or more risk
factors: performance status >3; moderate/severe hepatic or
renal impairment, age over 75. The incidence of severe tox-
icity is minimised by avoiding patients with these risk factors
and using the escalating schedule.
Haematopoietic growth factors were not used during this
study, and three observations suggest that the routine use of
granulocyte or granulocyte-macrophage colony-stimulating
factor for 'poor-risk' patients would not have been helpful:
(1) The risk factors for toxicity appeared also to predict for
failure to respond.
(2) Severe neutropenia, when it occurred, was accompanied
by thrombocytopenia.
(3) Response did not correlate positively with myelotoxicity
overall.
A policy of patient selection to avoid severe toxicity would
therefore seem more appropriate than one of 'treat and
rescue'. However, growth factors may, of course, be appro-
priate in cases of unexpected severe neutropenia.
Etoposide's oral bioavailability shows marked inter- and
intra-patient variability (Harvey et al., 1985). Once absorbed,
it is largely bound to plasma proteins, with free drug being
cleared by both renal and hepatic routes. There is therefore
much potential net variability in the pharmacokinetics of the
drug in cancer patients, who may have altered gastrointes-
tinal function, hypoproteinaemia and hepatic or renal dys-
function. Pharmacokinetic monitoring and dose adjustment
in our patient with renal impairment failed to prevent exces-
sive toxicity, however hypoalbuminaemia with consequently
reduced protein binding may have confounded the phar-
macokinetic monitoring in this case.
The stimulus to the development of protracted oral
etoposide schedules is the hypothesis that, in small cell lung
cancer, a pharmacodynamic relationship exists between
etoposide's anti-tumour activity and the duration for which
plasma levels are maintained above a low threshold value in
the region of 1 ;Lg ml-' (Slevin, 1990). The schedule of
50 mg b.d. used in this study produces plasma etoposide
> 1 ltg ml-' for a median of 14 h out of every 24 (Joel et al.,
1991b). However, the prolonged drug exposure provided in
this study has not resulted in improved activity compared
with previous reports of 3 or 4 day intravenous or oral
schedules (Kuhnle et al., 1988; Kavanagh et al., 1989; Eck-
hardt et al., 1990; Hillcoat et al., 1985; Hansen et al., 1990).
There are several possible explanations for this:
(1) A 4 day schedule may be long enough to exploit fully
any schedule dependency of etoposide in ovarian cancer,
with no additional benefit from more prolonged schedul-
ing.
(2) The patient population may be different: the largest and
most optimistic study of intravenous etoposide was in
patients with only one previous chemotherapy exposure
(Kuhnle et al., 1989).
(3) The variable oral bioavailability of etoposide may result
in failure to reach the threshold concentration for
activity in a proportion of the patients. Continuous
ambulatory intravenous infusion would provide a
superior, if less convenient, means of maintaining con-
sistent prolonged low plasma levels (Greco et al., 1992).
Alternatively, etoposide phosphate, a water-soluble pro-
drug with improved oral bioavailability in animal
studies, may provide a future solution to the problem of
oral etoposide dosing.
In conclusion, oral etoposide has significant activity
against relapsed and platinum-resistant ovarian cancer and
bears comparison with the best alternative intravenous
therapies. It should be employed with caution: patients who
are elderly, of poor performance status or with moderate to
severe hepatic or renal impairment may suffer severe
myelotoxicity, not necessarily preventable by pharmaco-
kinetic-guided dose adjustment, and are in any case unlikely
to benefit from treatment. Conversely, relatively fit patients
may benefit from this outpatient treatment, whose main tox-
icity when properly monitored is reversible alopecia. Con-
tinuous ambulatory intravenous infusion of etoposide is an
alternative means of providing optimal prolonged-schedule
therapy and is currently under investigation.
We are indebted to Rod Cummings, Catherine Oakley, Julie Clark,
Uma Samasundrum, Rita Winright and Nancy Preston for the col-
lection of data, and to the many doctors and nurses who have been
involved in the care of the patients reported.
References
BELINSON, J.L., PRETORIUS, R.G., MCCLURE, M. & ASHIKAGA, T.
(1986). Hexamethylmelamine, methotrexate, 5-fluorouracil as
second-line chemotherapy after platinum for epithelial ovarian
malignancies. Gynecol. Oncol., 23, 304-309.
BENEDETI-PANICI, P., SCAMBIA, G., GREGGI, S., SALERNO, G.,
CENTO, R. & MANCUSO, S. (1990). Doxorubicin and cyclophos-
phamide alternated with bleomycin and mitomycin C as a
second-line regimen in advanced ovarian cancer resistant to
cisplatin-based chemotherapy. Oncology, 47, 296-298.
CLARK, P.I., COTTIER, B., JOEL, S.P., THOMPSON, P.I. & SLEVIN,
M.L. (1990). Prolonged administration of single-agent oral
etoposide in patients with untreated small-cell lung cancer
(meeting abstract). Proc. Am. Soc. Clin. Oncol., 9, 226 (abstract
874).
COLEMAN, R., CLARK, J., GORE, M., WILTSHAW, E., SLEVIN, M. &
HARPER, P. (1989). A phase II study of mitozantrone in
advanced carcinoma of the ovary. Cancer Chemother. Pharmacol.,
24, 200-202.
COLEMAN, R., TOWLSON, K., WILTSHAW, E., SLEVIN, M., BLAKE,
P., STEIN, R., COOMBES, R. & HARPER, P. (1990). Epirubicin for
pretreated advanced ovarian cancer (letter). Eur. J. Cancer, 26,
850-851.
ECKHARDT, S., HERNADI, Z., THURZO, L., TELEKES, A., SOPKOVA,
B., MECHL, Z., PAWLICKI, M. & KERPEL-FRONIUS, S. (1990).
Phase II clinical evaluation of etoposide as a second-line treat-
ment in ovarian cancer. Oncology, 47, 289-295.
EINZIG, A.I., WIERNIK, P.H., SASLOFF, J., RUNOWICZ, C.D. &
GOLDBERG, G.L. (1992). Phase II study and long-term follow-up
of patients treated with taxol for advanced ovarian adenocar-
cinoma. J. Clin. Oncol., 10, 1748-1753.
GRECO, F.A., JOHNSON, D.H. & HAINSWORTH, J.D. (1990). Chronic
daily administration of oral etoposide. Semin. Oncol., 17 (suppl.
2), 71-74.PROTRACTED ORAL ETOPOSIDE FOR OVARIAN CANCER 195
GRECO, F.A., GARROW, G.C., JOHNSON, D.H., HANDE, K.R., STEIN,
R.S. & HAINSWORTH, J.D. (1992). Prolonged continuous infusion
of low dose etoposide in responsive neoplasms: preliminary phase
I/II results (meeting abstract). Proc. Am. Soc. Clin. Oncol., 11,
115 (abstract 282).
HANSEN, F., MALTHE, I. & KROG, H. (1990). Phase-II clinical trial
of etoposide administered orally in advanced ovarian cancer.
Gynecol. Oncol., 36, 369-370.
HARVEY, V.J., SLEVIN, M.L., JOEL, S.P., SMYTHE, M.M., JOHNSTON,
A. & WRIGLEY, P.F.M. (1985). Variable bioavailability following
repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol., 21,
1315-1319.
HILL, B.T., WHELAN, R.D.H., RUPNIAK, H.T., DENNIS, L.Y. &
ROSHOLT, M.A. (1981). A comparative assessment of the in vitro
effects of drugs on cells by means of colony assays or flow
microfluorimetry. Cancer Chemother. Pharmacol., 7, 21-26.
HILLCOAT, B.L., CAMPBELL, J.J., PEPPERELL, R., QUINN, M.A.,
BISHOP, J.F. & DAY, A. (1985). Phase-Il trial of VP-16-213 in
advanced ovarian carcinoma. Gynecol. Oncol., 22, 162-166.
JOEL, S., CLARK, P. & SLEVIN, M. (1991a). Renal function and
etoposide pharmacokinetics: is dose modification necessary?
(meeting abstract). Proc. Am. Soc. Clin. Oncol., 10, 103 (abstract
281).
JOEL, S.P., DOLEGA-OSSOWSKI, E., JONES, K., CLARK, P.I., JOHN-
SON, P. & SLEVIN, M.L. (199lb). The bioavailability of oral
etoposide during prolonged oral administration and development
of a limited sampling strategy for the estimation of AUC after an
oral dose (meeting abstract). Proc. Am. Assoc. Cancer Res., 32,
178 (abstract 1061).
KAVANAGH, J.J., MORRIS, M., SMALLDONE, L., KWAN, J. &
AMMERMAN, M.B. (1989). A randomized trial of carboplatin
versus variably timed continuous infusion etoposide in refractory
epithelial ovarian cancer (meeting abstract). Proc. Am. Soc. Clin.
Oncol., 8, 163 (abstract 637).
KUHNLE, H., MEERPOHL, H.G., LENAZ, L., ACHTERRATH, W.,
POHL, J., ROBEN, S., ALFUB, S., PFLEIDERER, A. & KUHN, W.
(1988). Etoposide in cisplatin-refractory ovarian cancer (meeting
abstract). Proc. Am. Soc. Clin. Oncol., 7, 137 (abstract 527).
LEE, C.R., NICHOLSON, P.W., SOUHAMI, R.L., SLEVIN, M.L., HALL,
M.R. & DESHMUKH, A.A. (1993). Patient compliance with pro-
longed low-dose oral etoposide for small cell lung cancer. Br. J.
Cancer, 67, 630-634.
McGUIRE, W.P., ROWINSKY, E.K., ROSENSHEIN, N.B., GRUMBINE,
F.C., ETTINGER, D.S., ARMSTRONG, D.K. & DONEHOWER, R.C.
(1989). Taxol: a unique antineoplastic agent with significant
activity in advanced ovarian epithelial neoplasms. Ann. Intern.
Med., 111, 273-279.
MANETTA, A., MACNEILL, C., LYTER, J.A., SCHEFFLER, B., POD-
CZASKI, E.S., LARSON, J.E. & SCHEIN, P. (1990). Hexamethyl-
melamine as a single second-line agent in ovarian cancer.
Gynecol. Oncol., 36, 93-96.
MARZOLA, M., ZUCCHETTI, M., COLOMBO, N., SESSA, C., PAGANI,
O., D'INCALCI, M., CAVALLI, F. & MANGIONI, C. (1993). Low-
dose oral etoposide in epithelial cancer of the ovary. Ann. Oncol.,
4, 517-519.
MILLER, J.C. & EINHORN, L.H. (1990). Phase II study of daily oral
etoposide in refractory germ cell tumours. Semin. Oncol., 17
(suppl. 2), 36-39.
PATER, J.L., CARMICHAEL, J.A., KREPART, G.V., FRASER, R.C.,
ROY, M., KIRK, M.E., LEVITT, M., BROWN, L.B., WILSON, K.S.,
SHELLEY, W.E. & WILLAN, A.R. (1987). Second-line chemo-
therapy of stage III-IV ovarian carcinoma: a randomized com-
parison of melphalan to melphalan and hexamethylmelamine in
patients with persistent disease after doxorubicin and cisplatin.
Cancer Treat. Rep., 71, 277-281.
SIMON, R.M. (1989). Design and conduct of clinical trials. In Cancer:
Principles and Practice of Oncology, 3rd edn., DeVita, V.T.,
Hellman, S. & Rosenberg, S.A. (eds) pp. 369-420.
SLEVIN, M.L. (1990). Low dose oral etoposide: a new role for an old
drug? (editorial). J. Clin. Oncol., 8, 1607-1609.
SLEVIN, M.L., CLARK, P.I., JOEL, S.P., MALIK, S., OSBORNE, R.J.,
GREGORY, W.M., LOWE, D.G., REZNEK, R.H. & WRIGLEY,
P.F.M. (1989a). A randomised trial to evaluate the effect of
schedule on the activity of etoposide in small-cell lung cancer. J.
Clin. Oncol., 7, 1333-1340.
SLEVIN, M.L., CLARK, P.I., JOEL, S.P., THOMPSON, P., TALBOT, D.,
PRICE, C. & WRIGLEY, P.F.M. (1989b). A randomised trial to
examine the effect of more extended scheduling of etoposide
administration in small cell lung cancer (meeting abstract). Proc.
Am. Soc. Clin. Oncol., 8, 236 (abstract 921).
SUTTON, G.P., BLESSING, J.A., HOMESLEY, H.D., BERMAN, M.L. &
MALFETANO, J. (1989). Phase II trial of ifosfamide and mesna in
advanced ovarian carcinoma: a Gynecologic Oncology Group
study. J. Clin. Oncol., 7, 1672-1676.
TRIMBLE, E.L., ADAMS, J.D., VENA, D., HAWKINS, M.J., FRIED-
MAN, M.A., CANETTA, R., ONETTO, N., HAYN, R. & ARBUCK,
S.G. (1993). Taxol in patients with platinum-resistant ovarian
cancer (meeting abstract). Proc. Am. Soc. Clin. Oncol., 12, 261
(abstract 829).
WHO (1979). WHO Handbookfor Reporting Results ofCancer Treat-
ment. World Health Organization Offset Publication No. 48:
Geneva.